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Abstract  
 
Whereas agonists bind directly in the heptahelical domain (HD) of most class-I 
rhodopsin-like G-protein coupled receptors (GPCRs), class-III agonists bind in the 
extracellular domain of their receptors. Indeed, the latter possess a large extracellular 
domain composed  of a cysteine-rich domain and a venus flytrap module (VFTM). 
Both the low sequence homology and the structural organization of class-III GPCRs 
raised the question of whether or not the HD of these receptors functions the same 
way as rhodopsin-like GPCRs. Here we show that the HD of metabotropic glutamate 
receptor 5 (mGlu5) displays the same agonist-independent constitutive activity as the 
wild-type receptor. Moreover, we show that the non-competitive antagonist MPEP 
and the positive allosteric modulator DFB act as inverse agonist and full agonist, 
respectively, on the mGlu5 HD in the absence of the extracellular domain. This 
illustrates that, like rhodopsin-like receptors, the HD of mGluRs can constitutively 
couple to G-proteins, and be negatively and positively regulated by ligands. These 
data show that the HD of mGluRs behave like any other class-I GPCRs in terms of 
G-protein coupling and regulation by various types of ligands. 
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Introduction 
G-protein coupled receptors (GPCRs) represent more than 1% of the total 
mammalian genes. They have been successful during animal evolution to recognize 
a wide range of stimuli from photon to large glycoproteins (1-3). These receptors 
transduce the extracellular signals in cellular responses via heterotrimeric G proteins. 
On the basis of sequence similarity, mammalian GPCRs have been classified into 
five major classes (3), but all share a common central domain composed of seven 
transmembrane helices, the heptahelical domain (HD). This domain is assumed to 
adopt various active and inactive conformations, the former being stabilized by 
agonists while the latter are stabilized by inverse agonists (4, 5). In most cases, these 
ligands directly interact in the heptahelical domain, but agonists can act within an 
additional extracellular domain (1, 6). This is the case of class-III GPCRs (7-10). 
Class-III GPCRs include receptors for the main neurotransmitters glutamate 
and GABA as well as receptors for Ca2+, sweet taste compounds and pheromones 
(10). Their agonist binding domain is homologous to bacterial periplasmic binding 
proteins involved in the trafficking of ions, amino-acids and sugars in the periplasm of 
gram-negative bacteria (7, 10, 11). This was confirmed by the determination of the 
crystal structure of the mGlu1 extracellular domain. This domain has a bilobate 
structure that adopts a closed conformation upon agonist binding in the cleft that 
separates both lobes (12, 13), and is often called a "Venus flytrap" module (VFTM). 
How agonist binding in the VFTM leads to the activation of the HD remains 
unknown.  However, the determination of the crystal structure of the mGlu1 VFTM 
with and without bound glutamate together with the demonstration that these 
receptors are constitutive dimers (14, 15) lead to a model for activation of class-III 
GPCRs (10, 12, 16). Accordingly, agonist binding in at least one VFTM of these 
dimeric receptors leads to a large conformational change of the dimer of VFTMs, 
possibly forcing the two HDs to interact with each other differently. This is expected 
to stabilize their active state. Such a peculiar structural organization of the receptor 
protein, associated with a very low sequence identity of their HD compared to that of 
other GPCRs, raised the question of whether or not the HDs of all GPCRs function 
the same way. 
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We previously reported that mGlu1a and mGlu5 metabotropic glutamate 
receptors (mGluRs) display constitutive activity (17, 18). A precise analysis of the 
constitutive activity of these receptors led us to propose that it resulted from a 
spontaneous activity of their HD rather than from a spontaneous closure of their 
VFTM (19). In agreement with this proposal, the non-competitive antagonists, MPEP 
and BAY36-7620, which bind in the HD (20, 21) are the only antagonists that display 
inverse agonist activity. 
 In the present study we examined whether the HD of such receptors could 
activate G-proteins in the absence of the VFTM. We found that mGlu5 HD was able 
to spontaneously activate Gq-type G-proteins, and that this constitutive activity could 
be inhibited by the known mGlu5 inverse agonist. Of interest, the positive modulator 
of mGlu5 receptor, although devoid of agonist activity on the wild-type receptor, acted 
as a full agonist on mGlu5 HD in the absence of the large extracellular domain. In 
summary, we provide novel insight on the mechanism of action of negative and 
positive allosteric modulators of class-III GPCRs. Moreover, our data show that the 
HD of class-III GPCRs displays constitutive activity and can be positively or 
negatively regulated by ligands, like any other class-I GPCRs. 
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Materials and methods 
Materials 
Glutamic acid was purchased from Sigma. L-Quisqualic acid and MPEP (2-methyl-6-
(phenylethynyl)-pyridine) hydrochloride were purchased from Tocris Cookson (Bristol; 
UK). Glutamate-pyruvate transaminase (GPT) was purchased from Roche (Basel, 
Switzerland). Culture medium, fœtal calf serum (FCS) and other products used for 
cell culture were purchased from GIBCO-BRL-Life Technologies, Inc. (Cergy 
Pontoise, France). [3H]myo-inositol (23.4 Ci/mol) was purchased from Amersham 
(Saclay, France).  
Contruction of mGlu5 mutants 
The construction of the N-terminal HA-tagged rat mGlu5a, pRKG5a-NHA, has been 
already described (22). The plasmid expressing the D5 mutant was obtained by 
inserting between the Mlu-I and Xba-I sites of pRK5-NHA, the mGlu5a cDNA coding 
for the HD and the C-terminal tail between the residues P568 and the C terminal end 
obtained by PCR. The final plasmid encodes for a protein possessing the signal 
peptide of mGlu5 followed by a HA tag and then by the HD and the intracellular 
C terminus of mGlu5a. The same strategy was used to generate D5D that 
corresponds to the mGlu5a HD segment between P568 and L864 (Fig. 1A). 
Cell culture and transfection 
HEK293 cells were cultured in Dulbecco’s modified Eagle’s medium supplemented 
with 10% FCS and transfected by electroporation as described elsewhere (23). Ten 
million cells were transfected with plasmid DNA encoding mGlu5 (0.6 µg), D5 (5 µg), 
D5D (5 µg) and completed to a total amount of 10 µg plasmid DNA with pRK6. To 
avoid any influence of glutamate in the assay medium released by the cells, the high 
affinity glutamate transporter EAAC1 was also co-transfected with the receptor. 
Synthesis of 3,3’-difluorobenzaldazine (DFB) 
3,3’-difluorobenzaldazine DFB was synthesized according to Buu-Hoi and Saint-Ruf 
(24). 
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Immunofluorescence 
Immunofluorescence assay was carried out as described elsewhere (22). Briefly, 24 
hours after transfection, cells platted on coverslips were washed with PBS and 
incubated for 90 minutes at 37°C with an anti-HA mouse monoclonal antibody (clone 
12CA5; Roche, Basel, Switzerland) at 1.33 µg/mL in PBS and 0.2% gelatine. The 
primary antibody was then detected with a Cy3 secondary antibody (1 µg/mL)  
(Jackson ImmunoResearch, West Grove, PA). Coverslips were mounted and 
observed using a Axiophot2 microscope (Zeiss, LePecq, France).  
Cell surface quantification by ELISA 
Twenty four hours after transfection, cells were washed twice with PBS, fixed with 
PBS and 4% paraformaldehyde and incubated for 30 minutes with an anti-HA rat 
monoclonal antibody (clone 3F10; Roche, Basel, Switzerland) (0.5 µg/mL) in PBS 
containing 5% FCS. Cells were then incubated with a secondary goat antibody 
conjugated to peroxydase (Jackson ImmunoResearch, West Grove, PA) (1 µg/mL). 
Secondary antibody was detected and quantified by chemiluminescence using 
Supersignal West Femto (Pierce, Rockford, IL) and a Wallac Victor2 luminescence 
counter (Molecular devices, St Gregoire, France). 
Inositol phosphate determination 
Inositol phosphate (IP) accumulation in transfected cells was performed in 96-well 
microplates after cell labeling overnight with [3H]myo-inositol. The IP formation 
determination was performed after a 30 minutes incubation in the presence of 10 mM 
LiCl and in the presence or absence of the indicated compounds. For basal 
determination of IP production, GPT (1U/ml) and 2 mM pyruvate were added to the 
reaction. The reaction was stopped with 0.1 M formic acid. Supernatants were 
recovered and IP produced were purified in 96 well plates by ion exchange 
chromatography using DOWEX resin. Radioactivity was measured using a Wallac 
1450 MicroBeta microplate liquid scintillation counter (Molecular devices, St 
Gregoire, France). Results are expressed as the amount of IP produced over the 
radioactivity present in the 10% triton X100 and 0.1 N NaOH-solubized membrane 
fraction, plus the produced IP. The dose-response curves were fitted using the 
GraphPad Prism program and the following equation:  
y=((ymax-ymin)/(1+(x/EC50)n))+ymin 
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Intracellular calcium measurements 
Cells were seeded after transfection in poly-ornithine coated black-walled, clear 
bottom 96-well plates and cultured for 24 hours. Cells were washed with freshly 
prepared buffer and loaded with 1 µM Ca2+-sensitive fluorescent dye Fluo-4AM 
(Molecular Probes, Leiden, The Netherlands) for 1 hour at 37°C. Cells were washed 
and incubated with 50 µL of buffer. A drug plate was prepared with the various 
concentrations of agonist to be tested and 50 µL of 2x-drug solution was added in 
each well after 20 seconds of recording. Fluorescence signals (excitation 485 nm, 
emission 525 nm) were measured using the fluorescence microplate reader 
Flexstation (Molecular devices, St Gregoire, France) at sampling intervals of 1.5 
second for 60 seconds.  
 
All data represented correspond to means ± SEM from representative experiments 
performed in triplicate. 
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Results 
Expression of wild-type and truncated  mGlu5 receptors 
To study the functional properties of mGlu5 HD, two truncated constructs were 
created. The first one, D5, was obtained by removing the VFTM and the cysteine-rich 
domain, and the second, D5D, was generated by truncating most of the C-terminal tail 
of D5 (Fig. 1A). Both N-terminal HA-tagged truncated mutants were expressed at the 
cell surface as shown by immunostaining of non-permeabilized cells (Fig. 1B). Under 
the same conditions, no fluorescence signal was detected at the surface of control 
cells transfected with the N-terminal HA-tagged GABAB1 subunit of the GABAB 
receptor that cannot reach the cell surface alone (25, 26) or with an empty pRK6 
plasmid (not shown). 
Surface expression of the HA-tagged mGlu5, D5 and D5D was then quantified 
using an ELISA assay. These experiments revealed that, for an equal quantity of 
plasmid DNA transfected in HEK293 cells, the two truncated mutants were 5 to 10 
times less expressed at the cell surface than wild-type receptor (not shown). In order 
to compare the functional properties of these constructs, conditions were set up to 
achieve a similar surface expression level as depicted in Fig. 1C. 
mGlu5, truncated  mutants are constitutively active 
The G-protein coupling activity of mGlu5, D5and D5D was examined by 
measuring IP accumulation. We found a higher IP formation in cells expressing any 
of these three constructs compared to mock-transfected cells (Fig. 2A). This basal 
activity represented 291, 211 and 284% of the control IP production, for mGlu5, D5 
and D5D, respectively. Among these three constructs, only the wild-type mGlu5 could 
be stimulated by glutamate (Fig. 2A). Even when applied at high concentration (up to 
10 mM, not shown), glutamate had no effect on the truncated mutants (Fig. 2A). 
These data show that the removal of the large extracellular domain suppresses the 
ability of glutamate to activate the receptor, but does not prevent the truncated 
constructs to activate G-proteins spontaneously. 
As mentioned above, the truncated receptors did not reach efficiently the cell 
surface, and accumulated in the ER. Therefore, it is possible that the observed high 
basal IP formation was due to the intracellular accumulation of mGlu5 receptors 
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rather than to a constitutive activity of the receptor at the cell surface. However we 
found that a longer version of D5D with 6 additional residues at the C-terminal end 
did not reach the cell surface and accumulated in the ER as shown by 
immunofluorescence studies and ELISA assays performed on intact and 
permeabilized cells (data not shown). No high basal IP formation could be measured 
in cells expressing this construct (data not shown). The same was true for a mGlu5 
chimeric construct bearing the ER retention signal of the GABAB1 receptor subunit 
(data not shown). This confirmed that the basal activity measured was mostly 
generated by receptors at the cell surface. 
Constitutive activity of D5 and D5D is inhibited by a negative allosteric 
modulator 
The non-competitive antagonist MPEP binds within the HD of mGlu5 (20, 27). 
This compound, often called a negative allosteric modulator, also inhibits the 
constitutive activity of mGlu5. As observed on the wild-type receptor (48.2 ± 15.1% 
inhibition, n=8), MPEP also inhibited 42.8 ± 1.5% (n=3) and 46.7 ± 15.3% (n=7) of 
the basal IP formation measured in cells expressing D5 and D5D, respectively (Fig. 
2B). These effects of MPEP were dose-dependent with IC50  values determined on 
D5 (7.6 ± 6.6 nM, n=3, not shown) or D5D (10.4 ± 6.6 nM, n=7) similar to that 
determined on mGlu5 (8.1 ± 4.3 nM, n=8) (Fig. 2B). These data confirm that basal IP 
formation measured in cells expressing D5 or D5D originates from a constitutive PLC 
activation by these constructs, and that MPEP does not require the extracellular 
domain of mGlu5 to interact with the receptor and acts as an inverse agonist. 
Furthermore, these data confirm the correct folding of the mGlu5 HD in the absence 
of both the large extracellular domain and the long C-terminal tail. 
In contrast to the wild-type receptor, the truncated mutants are activated by a 
positive allosteric modulator 
Recently, positive allosteric modulators of various mGlu receptors have been 
identified (10, 28, 29). Such compounds display no or very low agonist activity, but 
largely potentiate the action of agonists interacting in the VFTM. Analysis of the 
putative binding site of the mGlu1  and mGlu2 modulators suggested that they bind in 
the HD of these receptors (29, 30). Very recently, DFB has been reported as a 
positive allosteric modulator of mGlu5 (31). In agreement with this study, we found 
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that DFB did not activate mGlu5 receptor when care was taken to remove as much as 
possible glutamate from the medium (Fig. 3). However, DFB potentiated the action of 
glutamate, decreasing its EC50 value 2 fold (32.2 ± 9.2 (n=9) to 17.4 ± 4.4 µM (n=4) 
in the absence and presence of 100 µM DFB, respectively) (Fig. 3A). The same 
effect was observed with the agonist quisqualate (EC50 23.1 ± 2.3 (n=5) and 13.1 ± 
5.5 nM (n=3) in the absence and presence of DFB, respectively, data not illustrated). 
The maximal effect of glutamate was however not modified by DFB. As shown in 
Fig.3B, DFB potentiated quisqualate-induced activation of mGlu5 with an EC50 value 
of 11.3 ± 1.4 µM. A similar effect of DFB was observed when the Ca2+ signal was 
measured in cells expressing mGlu5 (Fig. 3A). 
The effect of DFB was then examined on the truncated receptors D5 and D5D. 
In contrast to what was observed with the wild-type receptor, DFB activated directly 
these constructs (Fig. 4A). This effect was dose-dependent with an EC50 value of 
12.9 ± 6.3 µM (n=6)(Fig. 4A) identical to that measured for the potentiating effect on 
the wild-type receptor (Fig. 3A). A similar effect was obtained with D5 (data not 
shown). DFB was also able to induce a Ca2+ signal in cells expressing D5 or D5D  
(Fig. 4B) with EC50 values of 20.2 ± 1.7 µM and 19.6 ± 1.2 µM, respectively. These 
data indicate that whereas DFB is a clear positive allosteric modulator devoid of 
agonist activity on mGlu5, it acts as an agonist on the truncated receptors. 
DFB-induced activity of D5D is close to the agonist-induced activity of  mGlu5 
In order to compare the activities of mGlu5 and D5D, cell surface expression 
and basal and agonist-induced IP production were measured in cells transfected with 
various amounts of plasmid DNA. Both basal and glutamate-induced IP productions 
were directly proportional to the amount of receptors at the cell surface, the slope of 
the correlation lines being indicative of the specific (amount of IP produced per 
receptor) basal and glutamate-induced activity of the receptor (Fig. 4C). When the 
same analysis was performed with ?5? in the absence and presence of DFB, the 
same correlation lines were obtained, showing that the specific constitutive activity of 
?5? is similar to that of mGlu5, and that DFB-induced activity of ?5? is similar to the 
glutamate-induced activity of the wild-type receptor (Fig. 4C). 
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Inhibition of the DFB-induced response of D5D by MPEP 
Since both DFB and MPEP were found to act on ?5?, we examined whether 
MPEP could inhibit the action of DFB. As shown in Fig. 5, MPEP inhibited the effect 
of DFB on IP production or increase in intracellular Ca2+ in cells expressing ?5?. 
However, even at high concentration, MPEP only partly inhibited the effect of DFB on 
D5D. This indicates a complex interaction between MPEP and DFB binding sites, in 
agreement with the partial inhibition of [3H]-methoxyPEPy (an analog of MPEP) 
binding by DFB on the wild-type receptor (31). 
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Discussion 
 
 The present study demonstrates that mGlu5 HD can activate PLC in the 
absence of both the large extracellular domain (the VFTM and the cysteine-rich 
domain) and the long C-terminal intracellular tail. Indeed, this domain of the mGlu5 
receptor displays a similar constitutive activity as the wild-type receptor. Moreover, 
we show that the inverse agonist MPEP conserved its activity on this truncated 
mutant. Finally, our data demonstrate that the positive allosteric modulator DFB is 
acting as a full agonist on this domain. These data shed light on the possible 
mechanism of action of such positive allosteric modulators of class-III GPCRs. 
 Our data clearly indicate that both the inverse agonist MPEP, and the positive 
allosteric regulator DFB do not need the large extracellular domain of mGlu5 to exert 
their action. Indeed, our data indicate that they directly interact within the HD of this 
receptor, therefore at a site distinct from the orthosteric ligand binding site located in 
the VFTM (10, 12). This is in agreement with the proposed binding site of the non-
competitive antagonists of mGlu5 (MPEP) (20, 27), and mGlu1 (21, 30, 32). Of 
interest, when a detailed analysis of these antagonists binding sites have been 
performed by site directed mutagenesis and molecular modeling, the binding pocket 
was found to be equivalent to that of retinal in rhodopsin (20, 27, 30). Although 
positive modulators of mGlu receptors have been identified only recently (28, 29, 31), 
one study analyzed the binding site of the mGlu2 potentiator LY487379 (29). In that 
case again, the binding pocket was found to be located within the HD, with important 
residues located in TM IV and V. In agreement with the latter study, our data also 
indicate the positive modulator DFB binds in the HD of mGlu5. However, the effect of 
DFB was not fully inhibited by MPEP in agreement with the reported partial inhibition 
of MPEP binding by DFB (31). This indicates a complex interaction between these 
two ligands suggesting they act at different sites. This reinforces the need for a 
detailed analysis of the DFB site. 
 Group-I mGluRs, mGlu1a, mGlu5a and mGlu5b display constitutive activity in 
heterologous expression systems (17, 18). The absence of inverse agonist activity of 
competitive antagonists known to prevent VFTM closure lead us to propose that the 
constitutive activity originates from the HD able to reach an active state even if the 
VFTM stays open (19, 21). In agreement with this possibility, non-competitive 
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antagonists interacting in the HD have inverse agonist activity (20, 21). Our present 
data showing the HD of mGlu5 displays the same constitutive activity as the wild-type 
receptor strongly support this idea. A kinetic model recently developed also 
confirmed this idea and, of interest, showed that the allosteric coupling between the 
VFTM and the HD is not strict (19). In other words, the change in conformation of one 
domain only influences the equilibrium constant between the two states of the other 
domain, but does not force it to adopt a specific conformation. Such a finding is likely 
of importance since we recently reported that the constitutive activity of group-I 
mGluRs is tightly regulated by the intracellular proteins Homer in neurons (33). As 
such, group-I mGluRs can be activated either by extracellular glutamate or by the 
intracellular protein Homer1a. The low allosteric coupling between the HD and the 
VFTM allows the intracellular protein Homer1a not to increase dramatically glutamate 
affinity. Thus, the receptor can retain its ability to be further activated by extracellular 
glutamate in a physiological range of concentration (19). 
 Our data confirm that the positive allosteric modulator of mGlu5, DFB is devoid 
of agonist activity on the wild-type receptor (it is not able to activate the full length 
receptor by itself) (31). We previously proposed that such a ligand is not able to 
directly stabilize the active state of the HD, but instead facilitates the active closed 
state of the VFTM to activate it (19). This proposal is clearly not consistent with our 
present data showing DFB activates the HD expressed alone to a similar extent as 
glutamate on the full length receptor. Accordingly, it appears that the presence of the 
VFTM prevents DFB from activating the HD, a conclusion not consistent with a weak 
allosteric coupling between the VFTM and the HD. How can one reconcile these 
observations? Recent findings revealed GPCRs likely exist in at least 3 states, a Rg 
(ground) state that corresponds to the totally inactive state stabilized by inverse 
agonists, a R state that is able to activate G-proteins though with a low efficacy, and 
a R* state that corresponds to the active state of the receptor stabilized by full 
agonists (34, 35). By analogy, we propose the HD of mGlu5 also exists in these 3 
states: HDg, HD and HD*. The equilibrium between HDg and HD may not be 
controlled by the VFTM. This equilibrium would be at the origin of the observed 
constitutive activity not inhibited by competitive antagonists, but by non-competitive 
ones directly acting in the HD (Fig. 6). In contrast, the HD* state would require the 
VFTM to be in the active state, such that DFB would not be able to activate the 
receptor without agonists. In contrast, in the absence of VFTM, the HD would be able 
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to reach more freely the fully active state HD* in the presence of DFB (Fig. 6). Since 
mGluRs are constitutive dimers, it is possible that the HD can oscillate between HDg 
and HD states  when the dimer of VFTMs is in the resting orientation (R in Fig. 6). On 
the other hand, when the dimer of VFTMs is in the active orientation (A in Fig. 6), the 
HD can reach the HD* state that is stabilized by DFB. Accordingly, it is possible that 
the formation of a specific form of the HD dimer is stabilized by DFB. However, 
further experiments are required to confirm this proposal. 
The periplasmic binding proteins are known to bind their ligand in the 
periplasmic space and to deliver it to a transmembrane complex responsible for the 
transport of the molecule inside the bacteria (11, 36). Among the hypotheses for the 
activation mechanism of class-III GPCRs, it was proposed that the VFTM would bind 
the ligand and deliver it to another site within the HD leading to its activation (37). Our 
data show that the mGlu5 HD cannot be activated by glutamate up to a concentration 
of 10 mM. This is not due to the inability of this domain to be activated since DFB can 
fully activate this domain. Such an observation favors therefore the second proposal 
that originates from the crystal structure of the mGlu1 VFTM (10, 12, 16). Indeed, this 
domain forms dimers and a large change in conformation of the dimer is observed 
upon agonist binding (Fig. 6). This is assumed to stabilize a specific conformation of 
the dimer of associated HDs leading to their activation (Fig. 6). As mentioned above, 
class-III VFTMs are not only involved in ligand binding but also in the dimerization 
process of these receptors (14, 15, 38). Such a dimer formation is assumed to be 
crucial for the intramolecular transduction between the VFTM and the HD (10). 
Whether dimerization of GPCRs is required for G-protein activation is still a matter of 
intense debate (39-42). At least our data show that the stabilization (and even 
disulfide cross-linking between the subunits) of class-III dimers by the VFTM is not 
required for the HD to activate G-proteins. Accordingly, either the HD can dimerize by 
itself, or dimerization is not required for G-protein activation. 
 There is actually a lot of pharmaceutical interests in identifying new allosteric 
modulators of mGluRs as potential new therapeutic agents. Our data show that the 
use of the HD of mGluRs may be a good tool to identify such new ligands since an 
agonist rather than a positive modulator has to be identified. The group of Conklin 
also highlighted the potential use of receptor activated solely by synthetic ligands 
(RASSL) (43). HDs of mGluRs may constitute new possibilities to develop such tools 
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that can be targeted in specific neuronal compartment not attainable with other 
mutant GPCRs. 
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Figure legends 
Figure 1. Cell surface expression of mGlu5, D5 and D5D. 
A. Schematic representation of mGlu5, D5 and D5D and location of the sites of 
truncation. VFTM stands for venus flytrap module, CRD for cysteine-rich domain and 
HD for heptahelical domain. The white box represents the HA tag and the grey box 
corresponds to the signal peptide of mGlu5. B. Surface expression of mGlu5, D5 and 
D5D in HEK 293 cells was detected by immunofluorescence on non permeabilized 
cells. C. Quantification of cell surface expression of mGlu5, D5 and D5D by ELISA on 
intact cells. Cells were transfected with 0.6, 5 and 5 µg of plasmids expressing 
mGlu5, D5 and D5D, respectively.  
Figure 2. Like mGlu5, D5 and D5D are constitutively active. 
A. IP production measured in mGlu5, D5 and D5D or mock transfected HEK 293 cells 
under basal conditions (white bars) or in the presence of 1 mM Glu (black bars). 
Basal IP formation in mock-transfected cell is highlighted by a dotted line. Data 
corresponds to the ratio between total IP produced by the cells and the total 
radioactivity remaining in the membranes plus the produced IPs. B. MPEP decreased 
the basal IP production in HEK293 cells expressing mGlu5 (open circles) and D5D 
receptors (closed circles).  Results are expressed as the percentage of the basal IP 
production measured in the absence of MPEP.  
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Figure 3. DFB potentiates agonist-induced activity of wild-type mGlu5. 
A. Effect of increasing concentrations of glutamate in the absence (CTR, open 
circles) or presence (DFB, closed circles) of 100 µM DFB on IP production in cells 
expressing mGlu5. B. Effect of increasing concentration of DFB was measured on 
cells expressing mGlu5 in the absence (open circles) or presence of 10 nM 
quisqualate (black circles). Insert: the effect of 10 nM quisqualate on intracellular 
Ca2+ concentration was measured under control condition (C) or in the presence of 
100 µM DFB (DFB). Vertical bar represents a change in the fluorescence signal of 
1000 units. Data are expressed as the percentage of the maximal effect measured 
with quisqualate plus DFB.  
Figure 4. Direct activation of D5D by the positive allosteric regulator DFB. 
A. Effect of increasing doses of DFB on D5D. DFB dose-dependently activates the 
truncated receptor D5D. The curve has been normalized such that the basal 
response is zero and the maximum is 100 %. Insert: IP formation (% above the 
basal) was induced by DFB only in cells expressing D5D and not in cells expressing 
mGlu5. B. Direct stimulation of D5 and D5D by 100 µM DFB as revealed by 
intracellular Ca2+ measurement with Fluo-4. C. Activity of mGlu5 (squares) and D5D 
(circles) as a function of their membrane expression. Cells were transfected with 
increasing amounts of cDNA coding for these receptors and surface expression of 
mGlu5 and ?5? was measured by ELISA on intact cells.  Basal (open symbols) and 
glutamate (1 mM) or DFB (1 mM) (closed symbols) induced IP formation were 
measured in parallel.  
Figure 5. MPEP inhibits partially DFB-induced activity on D5D. 
A. Effect of 10, 30 and 100nM MPEP on IP production induced by 300 µM DFB in 
cells expressing D5D. B. Effect of 10 and 100nM MPEP on intracellular Ca2+ release 
induced by 300 µM DFB on cells expressing D5D.  
Figure 6. Schematic representation of the possible action of inverse agonists 
and positive modulators of mGlu5 receptor. 
Top: the constitutive dimer of mGlu5 is shown to be composed of a VFTM (top), a 
cystein-rich domain (middle) and a HD. The HD is proposed to oscillate between a 
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slightly active state (HD) and a totally inactive ground state (HDg), the latter being 
stabilized by inverse agonist. This equilibrium can occur even though the dimer of 
VFTM stays in the resting state (R). The dimer of VFTMs is assumed to reach an 
active orientation (A) in the presence of agonist, leading to the stabilization of a fully 
active state of the dimer of HDs (HD*). The positive allosteric modulator, DFB, is 
proposed to bind with a higher affinity on HD*, stabilizing the fully active state of the 
receptor, leading to an increased affinity of the receptor for agonists (19). Bottom: in 
the absence of the large extracellular domain, the HD can reach more freely the fully 
active state HD* allowing the positive modulators to act as full agonists. 
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